Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance

Cell Cycle

Volumn 9, Issue 11, 2010, Pages 2051-2052

  Stoeltzing, Oliver ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; Cancer; Hsp90; mTOR; Resistance; Signaling

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; STAT3 PROTEIN; VASCULOTROPIN;

CANCER CELL; CANCER THERAPY; EDITORIAL; ENDOTHELIUM CELL; LIVER CARCINOGENESIS; ONCOGENE; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 77953593619     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.11.11924     Document Type: Editorial

References (11)

1. Guba M, et al. Nat Med 2002; 8:128-35.
2. Phung TL, et al. Cancer Cell 2006; 10:159-70.
3. Stoeltzing O, et al. Cancer Cell 2006; 10:89-91.
4. Lang SA, et al. Biochim Biophys Acta 1803:435-42.
5. Lang SA, et al. Hepatology 2009; 49:523-32.
6. Isaacs JS, et al. Cancer Cell 2003; 3:213-7.
7. Zhang H, et al. J Mol Med 2004; 82:488-99.
8. Lang SA, et al. Mol Cancer Ther 2007; 6:1123-32.
9. Sanderson S, et al. Mol Cancer Ther 2006; 5:522-32.
10. Takahashi S, et al. J Biol Chem 2003; 278:30821-7.
11. Rini BI, et al. Lancet Oncol 2009; 10:992-1000.